Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Claforan
(United States) [Available]Synonyms :
Cefotaxime
Class :
Cephalosporins and 3rd Generation
Brand Name :
Claforan
(United States) [Available]Synonyms :
Cefotaxime
Class :
Cephalosporins and 3rd Generation
Dosage forms and strengthsÂ
Injectable solution   Â
20mg/ml   Â
40mg/ml   Â
Powder for injection   Â
500mg   Â
1g   Â
2g   Â
10g
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
Cesarean Section:
1 g IV given as soon as the umbilical cord clamped
additional 1 g IM or IV given at six and 12hrs after the initial dose
1 g IM or IV every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
0.5 g IM given once for urethritis or cervicitis
0.5 g IM given once for Rectal gonorrhea (females)
1 g IM given once for Rectal gonorrhea (males)
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
Dosage forms and strengthsÂ
Injectable solution   Â
20mg/mL   Â
40mg/mL   Â
Powder for injection   Â
500mg   Â
1g   Â
2g   Â
10g   Â
0-1 week: 50 mg per kg IV every 12hrs
1-4 weeks: 50 mg per kg IV every 8hrs
Age: 1 month-12 years
for weight: <50 kg
50-180 mg per kg IM or IV given per day divided in 4 to 6 equal doses
for weight: >50 kg
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
Age: >12 years:
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
Higher doses are given to treat more severe or serious infections
0-1 week: 50 mg per kg IV every 12hrs
1-4 weeks: 50 mg per kg IV every 8hrs
Age: 1 month-12 years
for weight: <50 kg
50-180 mg per kg IM or IV has given per day divided into 4 to 6 equal doses
for weight: >50 kg
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
Age: >12 years
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
Higher doses are given to treat more severe or serious infections
0-1 week: 50 mg per kg IV every 12hrs
1-4 weeks: 50 mg per kg IV every 8hrs
Age: 1 month-12 years
for weight: <50 kg
50-180 mg per kg IM or IV has given per day divided into 4 to 6 equal doses
for weight: >50 kg
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
Age: >12 years:
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
Higher doses are given to treat more severe or serious infections
0-1 week: 50 mg per kg IV every 12hrs
1-4 weeks: 50 mg per kg IV every 8hrs
Age: 1 month-12 years
for weight: <50 kg
50-180 mg per kg IM or IV has given per day divided into 4 to 6 equal doses
for weight: >50 kg
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
Age: >12 years:
1 g IM or IV given every 12hrs for mild conditions
1-2 g IM or IV every 8hrs moderate to severe infections
2 g IV every 6-8hrs high dosing for infections
2 g IV every 4hrs for life-threatening infections
12 g is the maximum dose required per day
Higher doses are given to treat more severe or serious infections
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
bazedoxifene conjugated estrogens
when both drugs are combined, there may be a decreased effect of bazedoxifene/conjugated estrogens by altering intestinal flora  
when both drugs are combined, there may be a decreased effect of dienogest/estradiol valerate by altering intestinal flora  
when both drugs are combined, there may be a decreased effect of ethinylestradiol by altering intestinal flora  
levonorgestrel oral ethinylestradiol ferrous bisglycinate
when both drugs are combined, there may be a decreased effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by altering intestinal flora  
when both drugs are combined, there may be an increased effect of cefotaxime by acidic (anionic) drug competition for renal tubular clearance  
sodium picosulfate magnesium oxide anhydrous citric acid
when both drugs are combined, there may be a decreased effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism  
when both drugs are combined, there may be an increased risk of adverse effects  
when both drugs are combined, there may be an increased risk of nephrotoxicity and ototoxicity  
when both drugs are combined, there may be an increased effect of warfarin by unspecified interaction mechanism  
cephalosporins may enhance the anticoagulant effect of vitamin K antagonistsÂ
cephalosporins may enhance the anticoagulant effect of vitamin K antagonistsÂ
cephalosporins may enhance the anticoagulant effect of vitamin K antagonistsÂ
cephalosporins may enhance the anticoagulant effect of vitamin K antagonistsÂ
cephalosporins may enhance the anticoagulant effect of vitamin K antagonistsÂ
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
it may diminish the excretion rate when combined with estradiol valerate resulting in a greater serum level
it may enhance the risk of nephrotoxicity when combined with phenylbutazone
cefotaxime has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
When loracarbef is used together with cefotaxime, the risk or seriousness of nephrotoxicity is enhanced
When cefotaxime is used together with piroxicam, this leads to increased risk or seriousness of nephrotoxicity
When cefmenoxime is used together with cefotaxime, this leads to enhanced risk or seriousness of nephrotoxicity
When cefotaxime is used together with proglumetacin, this leads to enhanced risk or seriousness of nephrotoxicity
may have an increased nephrotoxic effect when combined with aminoglycosides
neomycin/polymyxin B/bacitracin topical
may have an increased nephrotoxic effect when combined with aminoglycosides
When cefotaxime is used together with benoxaprofen, this leads to enhanced risk or seriousness of nephrotoxicity
cefotaxime leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefotaxime leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
cefotaxime leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
cefotaxime leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
cefotaxime leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When cefotaxime is used together with difenpiramide, this leads to enhanced risk or seriousness of nephrotoxicity
cefotaxime may decrease the excretion rate of almasilate, leading to higher serum levels
may increase the nephrotoxic effect of cephalosporins
neomycin/polymyxin B/bacitracin topical
may increase the nephrotoxic effect of cephalosporins
may increase the nephrotoxic effect of cephalosporins
may increase the nephrotoxic effect of cephalosporins
may increase the nephrotoxic effect of cephalosporins
may increase the anticoagulant effect of cephalosporins
may increase the anticoagulant effect of cephalosporins
may increase the anticoagulant effect of cephalosporins
may increase the anticoagulant effect of cephalosporins
may increase the anticoagulant effect of cephalosporins
cefotaxime might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
when both drugs are combined, there may be an increased effect of aminohippurate sodium by acidic   drug competition for renal tubular clearance  
when both drugs are combined, there may be an increased risk of adverse effects  
choline magnesium trisalicylate
when both drugs are combined, there may be an increased effect of choline magnesium trisalicylate by acidic drug competition for renal tubular clearance  
when both drugs are combined, there may be an increased effect of cefotaxime by acidic drug competition for renal tubular clearance  
when both drugs are combined, there may be an increased effect of sulfasalazine by acidic drug competition for renal tubular clearance  
when both drugs are combined, there may be an increased effect on willow bark by acidic drug competition for renal tubular clearance 
Actions and spectrum:Â
Action:Â
Cefotaxime blocks bacterial cell wall synthesis by binding to and inhibiting penicillin-binding proteins, ultimately causing bacterial cell death.Â
Frequency defined  Â
1% to 10%  Â
Injection Site Inflammation  Â
Pain  Â
Induration  Â
Tenderness  Â
Colitis  Â
Diarrhea  Â
Nausea  Â
Urticaria  Â
Vomiting  Â
Frequency Not Defined  Â
Hepatitis  Â
Jaundice  Â
Toxic epidermal necrolysis  Â
Stevens-Johnson syndrome  Â
Erythema multiforme  Â
Elevated Blood Urea Nitrogen (BUN) And Creatinine  Â
Elevated Hepatic Transaminases  Â
Eosinophilia  Â
Fever  Â
Pruritus  Â
Rash  Â
Thrombocytopenia  Â
Transient Neutropenia  Â
Blackbox warning Â
None
Contraindication/CautionÂ
Contraindication:Â
Individuals with a known hypersensitivity or allergy should not use cefotaxime drug. Â
Caution: Â
Cefotaxime should be used cautiously by patients with a history of gastrointestinal diseases or renal impairment.Â
Pregnancy warnings:    Â
AU TGA pregnancy category: B1 Â
US FDA pregnancy category: B Â
Breastfeeding warnings: Â
The release of the drug into the human breastmilk is known  Â
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits      Â
Category X: Drugs listed in this category outweigh risks over benefits Hence these categories of drugs need to be avoided by pregnant women      Â
Category N: There is no data available for the drug under this category     Â
Pharmacology:Â
Cefotaxime is effective against a broad range of bacteria, including both gram-positive and gram-negative types. Â
Pharmacodynamics:Â
Cefotaxime kills bacteria by duration of exposure, requiring concentrations above the minimum inhibitory level for optimal eradication.Â
Pharmacokinetics:Â
Limited information available on ADME.Â
Administration:Â
The route of administration is intravenous and intramuscularÂ
Patient Information Leaflet  Â
Generic Name: cefotaxime Â
Pronounced: cef· o· tax· ime Â
Why do we use cefotaxime? Â
A third-generation cephalosporin cefotaxime is used to treat bacterial infections that are susceptible to both Gram-positive and Gram-negative bacteria. Â
It is indicated to treat gonorrhoea, meningitis, and severe infections including infections of the kidney and urinary system.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
